
    
      The study consists of four groups of children recruited in different centers in Finland. One
      group of children will receive the existing formulation of HRV vaccine and one group will
      receive the new formulation of the HRV vaccine. The other two groups will receive the placebo
      for existing formulation or the new formulation based on the allocation. The vaccine or
      placebo will be administered starting at 6 - 12 weeks of age according to 0, 1 month
      schedule. Routine childhood vaccinations are allowed according to local practice, but at
      least 14 days apart from each dose of study vaccine. The duration of the study will be
      approximately 2 months per child.
    
  